2-(4-Isopropylphenoxy)-N,N-dimethylethanamine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(4-Isopropylphenoxy)-N,N-dimethylethanamine
• 英文别名: N,N-dimethyl-2-(4-propan-2-ylphenoxy)ethanamine
• 化学式: C₁₃H₂₁NO
• 分子量: 207.31
• InChiKey: UNXXJCYWBAALFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel Heterocyclic Compounds and Uses Thereof
  申请人：Huang Zilin

  公开号：US20130210818A1

  公开（公告）日：2013-08-15

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  提供了新的替代杂环化合物，含有它们的组合物，以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独使用，也可以与至少一种额外的药物联合使用，用于治疗由Raf激酶介导的疾病，如癌症。
• SULFONYL-SUBSTITUTED BENZOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD AND MEDICAL USE THEREOF
  申请人：SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD

  公开号：US20190300506A1

  公开（公告）日：2019-10-03

  The present invention relates to a sulfonyl-substituted benzoheterocyclic derivative, a preparation method and medical use thereof. Particularly, disclosed is a compound of formula (I) or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, and a preparation method and application thereof. The definition of each group in the formula can be found in the specification and the claims.

  本发明涉及一种磺酰基取代的苯杂环衍生物，其制备方法和医疗用途。特别地，公开了一种符合式(I)的化合物或其药学上可接受的盐、立体异构体、溶剂合物或前药，以及其制备方法和应用。在公开说明书和权利要求中可以找到该式中每个基团的定义。
• Substituted Fused Pyrroleoximes and Fused Pyrazoleoximes
  申请人：Maynard George

  公开号：US20080032975A1

  公开（公告）日：2008-02-07

  Disclosed are compounds of the formula and the pharmaceutically acceptable salts thereof wherein R, Ar, A, n, R 1 and R 2 are defined herein. These compounds are highly selective agonists, antagonists or inverse agonists for GABA A brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA A brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Down Syndrome, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are also disclosed.

  本发明涉及以下式的化合物及其药学上可接受的盐，其中R、Ar、A、n、R1和R2的定义如下。这些化合物是高度选择性的GABAA脑受体的激动剂、拮抗剂或反向激动剂，或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药，因此可用于诊断和治疗焦虑症、抑郁症、唐氏综合征、睡眠和癫痫障碍、苯二氮卓类药物过量和增强记忆。还公开了包括包装的药物组合物在内的制药组合物。
• Orthogonal gene switches
  申请人：Ciliberto Gennaro

  公开号：US20070087346A1

  公开（公告）日：2007-04-19

  The present invention relates to an orthogonal gene switch for regulating the expression of a desired gene. The gene switch comprises a chimeric transcription factor that does not respond to endogenous ligands, and a ligand that is capable of activating the chimeric transcription factor but not endogenous transcription factors. The present invention also relates to the method of constructing the orthogonal gene switch.

  本发明涉及一种正交基因开关，用于调节所需基因的表达。该基因开关包括一个嵌合转录因子，不响应内源性配体，以及一种配体，能够激活嵌合转录因子，但不能激活内源性转录因子。本发明还涉及构建正交基因开关的方法。
• Novel heterocyclic compounds and uses therof
  申请人：Hunag Zilin

  公开号：US20100003246A1

  公开（公告）日：2010-01-07

  New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.

  本文提供了新的取代杂环化合物、含有它们的组合物以及使用它们抑制Raf激酶活性的方法。这些新化合物和组合物可以单独或与至少一种其他药物联合使用，用于治疗Raf激酶介导的疾病，如癌症。